drugset / Trial / NCT06811272
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.
Timeline
- Start
- 2025-06-05
- Primary completion
- 2026-10-01
- Completion
- 2028-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epcoritamab | Monoclonal antibody | — | Subcutaneous |